🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million new cases annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Results and Global Access

According to findings published in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have shared positive views. The availability of a easy-to-administer therapy like this is described as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.